SOPHiA DDM™ GIInger Genomic Integrity Solution
Unlock genomic insights with a universal key
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Empower your homologous recombination deficiency (HRD) analysis with our deep learning algorithm, GIInger™
SOPHiA DDM™ GIInger Genomic Integrity Solution accurately defines the genomic instability status of ovarian cancer samples. Designed to analyze whole genome sequencing data, it offers a flexible, in-house approach that complements your capture-based BRCA analysis for a complete HRD assessment.
Complementary to BRCA analysis
Seamlessly integrate GIInger™ into capture-based laboratory workflows, without the need for extra sample processing.
Low-pass whole genome sequencing (WGS)
Leverage coverage profiles from low-pass WGS data, requiring only ~1x coverage depth (minimum ~0.4x).
Robust, deep learning-based analysis
Reveal genomic instability status of FFPE ovarian cancer samples with the powerful GIInger™ algorithm.
Streamlined, technology-agnostic workflow
Save time with a FASTQ-to-report workflow, designed to be compatible with multiple wet lab and sequencing technologies.
Integrated tertiary analysis and reporting
Increase efficiency with evidence-based decision support and reporting features of OncoPortal™ Plus.
Collective intelligence
Access SOPHiA GENETICS Community, one of the largest knowledge-sharing networks of connected healthcare institutions.
Spice up your analysis with GIInger™
Current approaches to measuring genomic instability require deep genomic profiling data (>30x coverage), which can be costly and difficult to implement in routine analysis1.
To overcome these limitations, our expert team developed the GIInger™ deep learning algorithm, exclusively available on the SOPHiA DDMTM Platform. GIInger™ leverages data from low-pass whole genome sequencing profiles (~1x coverage) to produce the Genomic Integrity Index (GII), a predictive score of a sample’s genomic instability status.
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Add the missing piece to your workflow
Designed to be compatible with with different capture-based workflows, SOPHiA DDM™ GIInger Genomic Integrity Solution offers a universal approach to genomic analysis that seamlessly integrates with your existing laboratory set-up with no impact on previous validation.
Adoption of our genomic applications is made easy with the SOPHiA DDM™ MaxCare Program, empowering teams to gain confidence in their results, establish workflow efficiency, meet quality standards, and ensure performance by offering comprehensive training and analytical performance assessment.
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Trust your data
High analytical concordance
In an equivalence study of 129 FFPE DNA samplesa from ovarian cancer tissue, the genomic instability status as determined by the SOPHiA DDM™ GIInger Genomic Integrity Solution (WGS workflow) was highly concordant with the status obtained with the SOPHiA DDM™ HRD Solution (targeted and whole genome sequencing workflow).
a50 ng, DQN>3, tumor content >30%. Samples were processed using SOPHiA DDM™ HRD Solution library prep workflow and sequenced using Illumina® NovaSeq™ 6000. SOPHiA DDMTM GIInger Genomic Integrity Solution is also verified for use with SOPHiA GENETICS™ Universal Library Prep.
Data on file.
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Expand identification of HRD-positive samples
Approximately 1 in 2 individuals with HRD-positive advanced ovarian cancer do not have a pathogenic BRCA mutation, however, they do show evidence of genomic instability or ‘scarring’2.
Measuring genomic instability status can help identify samples that are BRCA wild-type but may still be sensitive to PARP inhibition2. By going beyond BRCA mutation detection, clinical researchers can maximize insights from genomic data and unlock the potential of precision oncology.
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
What do our customers think?
The SOPHiA GENETICS team enabled a seamless integration of GIInger™ algorithm into our already validated in-house capture-based library preparation. We are now able to test the Genomic Integrity Index for all our ovarian cancer samples quickly, accurately, and seamlessly.
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Specifications
Application type | Dry lab solution (bioinformatics pipeline) |
Sample type | FFPE or FF ovarian cancer tissue |
WGS coverage depth | ~1x recommended (0.4x minimum) |
Limit of detection | 30% tumor content |
Sequencer compatibility | Illumina NextSeq® 550 and NovaSeq™ 6000 |
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Resources
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Related genomic solutions
![pink-dots-icon-retina pink dots icon](https://www.sophiagenetics.com/wp-content/uploads/2021/05/pink-dots-icon.png)
Want to know more?
Get in touch with us.
References
- Konstantinopoulos PA, et al. Cancer Discov. 2015;5(11):1137-54
- Colombo N, Ledermann JA. Ann Oncol. 2021;32(10):1300-3